Erin Quirk, Terns Pharmaceuticals president and head of R&D
Terns Pharmaceuticals touts mid-stage success for NASH drug, stock falls
Terns Pharmaceuticals said a high dose of its experimental oral NASH treatment helped reduce liver fat in a Phase IIa trial.
The Foster City, CA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
